Novo Nordisk A/S (NVO)
| Market Cap | 286.26B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.40 |
| PE Ratio | 19.54 |
| Forward PE | 15.68 |
| Dividend | $1.18 (1.78%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 2,803,713 |
| Open | 65.52 |
| Previous Close | 64.92 |
| Day's Range | 65.45 - 66.97 |
| 52-Week Range | 57.00 - 139.74 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 112.00 (+68.35%) |
| Earnings Date | Aug 6, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $112.0, which is an increase of 68.35% from the latest price.
News
Novo Nordisk's Moat Is Deeper Than You Think
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of...
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
Fangzhou Inc., a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company.
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Patients a...
Novo Nordisk Has So Much Room To Go
Novo Nordisk's Q1 2025 results were solid, but FY guidance was cut, suggesting a longer recovery. Large growth potential exists, with 85% of diabetes patients undertreated and obesity treatments under...
Novo Nordisk: The Market Doesn't Get It
Novo Nordisk remains dominant in diabetes and obesity care, with strong growth and expanding market share despite recent investor concerns. The company's pipeline, especially the oral GLP-1 and Alzhei...
3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies
I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently me...
Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's ...
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Novo Nordisk: Reclaiming Market Share
Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects due to rising global demand and a robust pipeline. Recent stock weakness is overdone; valuation models s...
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving...
Italy set to speed through $2.3 billion Novo Nordisk investment
Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome.
Novo Nordisk's Sell-Off Has Gone Too Far
Novo Nordisk's recent sell-off is overdone; current fears around pricing and CagriSema are temporary, creating a compelling buying opportunity. The company's fundamentals remain strong, with robust sa...
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding ...
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Insight: How Novo Nordisk misread the US market for its weight loss sensation
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable ...
Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
Novo Nordisk ties up with WeightWatchers to sell Wegovy
Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on ...
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...
Weight loss and diabetes jabs linked to potentially fatal side effect
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.
The Best European Stocks to Buy
European stocks are cheaper than their U.S. counterparts, and there are plenty of high-quality companies to choose from. Here's how you can find them.
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff' Wegovy
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers' ...